New test may predict immunotherapy success in bladder cancer

NCT ID NCT06738797

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new lab test called SPHERTEST to see if it can predict how well bladder cancer patients will respond to immunotherapy. Researchers will take blood and tumor samples from 32 patients with advanced bladder cancer to see if the test's prediction matches real treatment outcomes. The goal is to find a way to personalize treatment and avoid giving ineffective therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Urogenital Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROGENITAL NEOPLASMS

Contacts and locations

Locations

CHU de Nimes
RECRUITING

Nîmes, France
Centre Antoine Lacassagne
NOT_YET_RECRUITING

Nice, France
Institut Régional du Cancer de Montpellier
NOT_YET_RECRUITING

Montpellier, France
Institut du Cancer de Montpellier
NOT_YET_RECRUITING

Montpellier, France
Iuct Oncopole
RECRUITING

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.